GSK, Pfizer Face Declining Respiratory Syncytial Virus Vaccine Sales Due To Narrow Age Recommendations
RSV vaccine sales from GSK and Pfizer have dropped significantly following revised CDC guidelines, narrowing the eligible age ...
GlaxoSmithKline (GSK) Gets a Hold from Kepler Capital
In a report released on October 10, David Evans from Kepler Capital maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), ...
FiercePharma3d
GSK will pony up $2.2B to resolve 80K Zantac cases
The agreement frees the British pharma giant from litigating 93% of the state court cases it faced in the U.S.
FTSE 100 opens higher on GSK boost
The UK's benchmark FTSE 100 opened higher on Thursday, led by gains in GSK following the settlement of lawsuits in the United ...
GSK’s problem is it has more than one source of pain
Zantac settlement should ease investors’ nervousness but long-standing concerns about drugmaker’s pipeline remain ...
GSK Bought More Shares of Biotech Wave Life Sciences
GSK paid $22.4 million on Sept. 27 for 2.8 million more shares of Wave Life Sciences for $8 each. GSK now owns 16.8 million ...
GSK: The Worst Is Finally Over (Rating Upgrade)
GSK's share price rose 6% after settling 93% of Zantac cases, impacting Q3 earnings; forward non-GAAP P/E remains reasonable ...
FTSE 100 Live 10 October: GSK shares rise on $2.2bn Zantac settlement, property firm gets £1.1bn bid
GSK’s $2.2 billion Zantac settlement today put its shares top of the FTSE 100, albeit still well short of their level before ...